Hospital
Amisub of South Carolina, INC.
Amisub of South Carolina, INC. was paid $34.53M by Medicaid between Jan 2018 and Dec 2024, across 285 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 14% of everything it billed.
33Billing provider infoAMISUB OF SOUTH CAROLINA, INC.
ROCK HILL, SC 29732
ROCK HILL, SC 29732
33aNPI1457382483assigned 07/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$34.53M
24GClaims1,237,494
24DCodes billed285
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#9 of 115
Median peer was paid$2.47M
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 219,727 | $4.84M | |
| 2019 | 207,720 | $4.64M | |
| 2020 | 171,553 | $4.81M | |
| 2021 | 176,943 | $5.21M | |
| 2022 | 163,765 | $5.51M | |
| 2023 | 164,689 | $5.76M | |
| 2024incomplete | 133,097 | $3.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 14% | 47,468 | 39,343 | $4.72M |
| J3490 | Unclassified drugs | 9.4% | 29,677 | 14,264 | $3.25M |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 8.0% | 58,922 | 23,606 | $2.78M |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 6.1% | 10,431 | 9,718 | $2.10M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 4.7% | 19,240 | 16,012 | $1.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.6% | 49,891 | 45,029 | $1.58M |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.4% | 20,656 | 16,359 | $1.53M |
| 36415 | Collection of venous blood by venipuncture | 3.6% | 9,046 | 7,419 | $1.26M |
| A0425 | Ground mileage, per statute mile | 2.9% | 33,058 | 25,698 | $1.00M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 2.9% | 13,366 | 10,700 | $987K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 11,027 | 10,250 | $967K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.6% | 8,363 | 6,219 | $905K |
273 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 3,825 | $789K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.0% | 7,055 | $680K |
| 81001 | 1.8% | 19,389 | $618K | |
| 99284 | Emergency room visit (serious) | 1.4% | 40,214 | $488K |
| 81003 | 1.3% | 23,047 | $458K | |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 22,433 | $411K |
| 81025 | 1.0% | 11,435 | $358K | |
| 87070 | <1% | 5,664 | $335K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,999 | $292K |
| A9150 | Non-prescription drugs | <1% | 10,667 | $271K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,437 | $262K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,828 | $259K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,165 | $248K |
| 87081 | <1% | 5,777 | $246K | |
| 59025 | Fetal non-stress test | <1% | 2,482 | $234K |
| J1815 | Injection, insulin, per 5 units | <1% | 2,421 | $212K |
| 87641 | <1% | 2,856 | $205K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,397 | $203K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 155 | $200K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 719 | $170K |
| 93971 | <1% | 1,788 | $167K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,017 | $149K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,749 | $147K |
| 99285 | Emergency room visit (most serious) | <1% | 26,891 | $145K |
| 73610 | <1% | 2,245 | $137K | |
| 77062 | <1% | 769 | $132K | |
| 82962 | <1% | 14,566 | $129K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,122 | $128K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 402 | $126K |
| 73130 | <1% | 2,012 | $123K | |
| 73560 | <1% | 3,276 | $120K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13,303 | $118K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,322 | $109K |
| 73630 | <1% | 2,361 | $106K | |
| 71250 | <1% | 728 | $96K | |
| 85027 | <1% | 5,924 | $95K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 8,918 | $94K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 144 | $91K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,127 | $91K |
| 12001 | <1% | 680 | $87K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,712 | $86K |
| 73030 | <1% | 2,329 | $86K | |
| 87420 | <1% | 2,187 | $85K | |
| 73110 | <1% | 1,541 | $85K | |
| 72100 | <1% | 3,082 | $81K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,077 | $77K |
| 85610 | <1% | 20,389 | $73K | |
| 76642 | <1% | 2,092 | $68K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 64,015 | $61K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 615 | $60K |
| 12011 | <1% | 326 | $60K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 455 | $57K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,187 | $55K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,291 | $55K |
| 74018 | <1% | 1,542 | $53K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 524 | $53K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,639 | $52K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 88 | $52K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21,908 | $51K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,161 | $46K |
| 73502 | <1% | 1,346 | $45K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,641 | $42K |
| 76830 | Ultrasound, transvaginal | <1% | 1,918 | $41K |
| 72050 | <1% | 682 | $34K | |
| C1769 | Guide wire | <1% | 1,007 | $33K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,005 | $32K |
| 82565 | <1% | 519 | $32K | |
| 93970 | <1% | 371 | $31K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 351 | $30K |
| 84112 | <1% | 116 | $29K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,313 | $29K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 651 | $29K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,109 | $28K |
| 11043 | <1% | 40 | $26K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 79 | $26K |
| 84702 | <1% | 4,990 | $25K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 613 | $24K |
| 73080 | <1% | 466 | $24K | |
| 72070 | <1% | 722 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,950 | $23K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,791 | $21K |
| 99218 | <1% | 5,073 | $21K | |
| G0378 | Hospital observation service, per hour | <1% | 1,643 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,968 | $18K |
| 73140 | <1% | 200 | $18K | |
| 87631 | <1% | 1,967 | $16K | |
| 73090 | <1% | 315 | $16K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 183 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,253 | $14K |
| 86886 | <1% | 2,777 | $14K | |
| 88304 | <1% | 1,470 | $14K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 20,947 | $13K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,740 | $13K |
| 73590 | <1% | 404 | $13K | |
| 84703 | <1% | 16,364 | $12K | |
| 74019 | <1% | 394 | $12K | |
| 77061 | <1% | 130 | $11K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 680 | $11K |
| 49083 | <1% | 19 | $11K | |
| 83735 | <1% | 18,969 | $11K | |
| 74022 | <1% | 583 | $11K | |
| 87400 | <1% | 4,408 | $10K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,493 | $10K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,218 | $10K |
| 80076 | <1% | 9,871 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,268 | $10K |
| 96376 | <1% | 3,349 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 797 | $9K |
| 87210 | <1% | 3,447 | $8K | |
| 80061 | Lipid panel | <1% | 2,421 | $8K |
| 76801 | <1% | 2,772 | $8K | |
| 76536 | <1% | 124 | $7K | |
| 72141 | <1% | 25 | $7K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 45 | $7K |
| 84484 | <1% | 24,385 | $7K | |
| 70486 | <1% | 306 | $7K | |
| A0998 | Ambulance response and treatment, no transport | <1% | 252 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,746 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,839 | $6K |
| 77065 | Tomosynthesis, mammo | <1% | 653 | $6K |
| 70360 | <1% | 104 | $6K | |
| 82550 | <1% | 11,412 | $6K | |
| 10060 | <1% | 95 | $6K | |
| L0174 | Cervical, collar, semi-rigid, thermoplastic foam, two piece with thoracic extension, prefabricated, off-the-shelf | <1% | 13 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 6,300 | $5K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,006 | $4K |
| 88307 | <1% | 391 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 402 | $4K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 28 | $4K |
| 84100 | <1% | 1,330 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,469 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,077 | $4K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 80 | $4K |
| 85730 | <1% | 16,374 | $3K | |
| 72170 | <1% | 373 | $3K | |
| 71101 | <1% | 45 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 999 | $3K |
| 82247 | <1% | 249 | $3K | |
| 84439 | <1% | 1,450 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 65 | $3K |
| 82270 | <1% | 233 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,922 | $3K |
| 93880 | <1% | 94 | $3K | |
| 73620 | <1% | 75 | $3K | |
| 87040 | <1% | 4,576 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,044 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $2K |
| 82805 | <1% | 680 | $2K | |
| 83690 | <1% | 18,003 | $2K | |
| 70491 | <1% | 66 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,923 | $2K |
| 97162 | <1% | 415 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,951 | $2K |
| 86140 | <1% | 2,423 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,222 | $2K |
| 85379 | <1% | 3,242 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,521 | $2K |
| 73562 | <1% | 38 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,072 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,872 | $2K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 66 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,119 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,559 | $2K |
| 85018 | <1% | 70 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,137 | $2K |
| 29125 | <1% | 150 | $2K | |
| 83605 | <1% | 9,251 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,302 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,182 | $1K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 60 | $1K |
| 76770 | <1% | 14 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,165 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,973 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 98 | $1K |
| 82728 | <1% | 102 | $933.24 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,023 | $928.48 |
| 87186 | <1% | 2,585 | $813.79 | |
| 76775 | <1% | 25 | $806.38 | |
| 73700 | <1% | 12 | $800.41 | |
| 83880 | <1% | 6,267 | $782.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 119 | $779.77 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,076 | $758.35 |
| 87077 | <1% | 1,158 | $698.28 | |
| 86900 | <1% | 3,170 | $679.82 | |
| 85652 | <1% | 1,656 | $679.53 | |
| 82272 | <1% | 37 | $674.26 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,997 | $621.89 |
| 29515 | <1% | 46 | $596.14 | |
| 88173 | <1% | 12 | $497.44 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,671 | $486.60 |
| 82607 | <1% | 130 | $451.47 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 704 | $418.18 |
| 73552 | <1% | 13 | $382.16 | |
| 12002 | <1% | 14 | $381.75 | |
| 72040 | <1% | 14 | $360.11 | |
| 73600 | <1% | 16 | $348.38 | |
| 76870 | <1% | 14 | $334.48 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,581 | $332.69 |
| 94664 | <1% | 437 | $310.24 | |
| 72131 | <1% | 46 | $303.28 | |
| 62323 | <1% | 51 | $278.25 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,825 | $260.06 |
| A0888 | Noncovered ambulance mileage, per mile (e.g., for miles traveled beyond closest appropriate facility) | <1% | 27 | $230.76 |
| 70498 | <1% | 55 | $221.09 | |
| 86901 | <1% | 5,951 | $213.24 | |
| 70496 | <1% | 14 | $191.53 | |
| 84550 | <1% | 157 | $171.26 | |
| 84156 | <1% | 480 | $160.62 | |
| 82570 | <1% | 505 | $132.03 | |
| 84145 | <1% | 1,304 | $128.38 | |
| 88342 | <1% | 675 | $125.33 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 63 | $124.10 |
| A4217 | Sterile water/saline, 500 ml | <1% | 269 | $84.38 |
| A9270 | Non-covered item or service | <1% | 1,207 | $41.86 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 639 | $34.27 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 795 | $30.00 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,413 | $24.31 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 438 | $22.61 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,476 | $17.95 |
| 82248 | <1% | 238 | $16.76 | |
| 85045 | <1% | 110 | $13.96 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 232 | $13.02 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 207 | $8.48 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 290 | $4.20 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,095 | $2.89 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,004 | $0.00 |
| 74174 | 0% | 111 | $0.00 | |
| 86920 | 0% | 145 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 255 | $0.00 |
| 36430 | 0% | 92 | $0.00 | |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 46 | $0.00 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 96 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 228 | $0.00 |
| 87205 | 0% | 96 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 24 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 73 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 51 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 84 | $0.00 |
| 19083 | 0% | 13 | $0.00 | |
| 90674 | 0% | 145 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 97 | $0.00 |
| 94760 | 0% | 42 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 155 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 42 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 34 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 71 | $0.00 |
| 86308 | 0% | 12 | $0.00 | |
| 82746 | 0% | 34 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 13 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 27 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 18 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 29 | $0.00 |
| 83615 | 0% | 19 | $0.00 | |
| 93458 | 0% | 12 | $0.00 | |
| 86592 | 0% | 14 | $0.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 29 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 300 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 409 | $0.00 |
| 82140 | 0% | 230 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 41 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 1,807 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 65 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 122 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 113 | $0.00 |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 79 | $0.00 |
| 83540 | 0% | 39 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 12 | $0.00 |
| 80305 | 0% | 14 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 14 | $0.00 |
| 36600 | 0% | 13 | $0.00 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 16 | $0.00 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 0% | 25 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILMORE, STEVE (CFO)